Loading clinical trials...
Loading clinical trials...
The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
October 1, 2025
Primary Completion Date
June 30, 2027
Completion Date
June 30, 2027
Last Updated
November 4, 2025
12
ESTIMATED participants
13C6-Glucose
DRUG
Lead Sponsor
Vanderbilt University Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07043478